Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
| Autor: | Luis A. Garza, Nicholas Girardi, Amy R. Vandiver, Jihad Alhariri |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Ruxolitinib Alopecia Areata Laboratory monitoring Administration Oral Dermatology Pharmacology Article 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Acute onset Nitriles Humans Medicine Dosing skin and connective tissue diseases Protein Kinase Inhibitors Janus Kinases integumentary system business.industry Alopecia Middle Aged Alopecia areata medicine.disease stomatognathic diseases Pyrimidines 030220 oncology & carcinogenesis Alopecia universalis Healthy individuals Acute Disease Chronic Disease Pyrazoles Community setting Female business medicine.drug |
| Zdroj: | International Journal of Dermatology. 56:833-835 |
| ISSN: | 0011-9059 |
| Popis: | Background Alopecia areata is a relatively common condition affecting patients seen in community dermatology clinics. A 2014 study implicated the JAK1/JAK2 inhibitor, ruxolitinib in short-term treatment of alopecia, however little information exists about the long-term use in otherwise healthy individuals in the community setting. Methods A patient with chronic alopecia areata and a patient with acute onset alopecia universalis were treated with oral ruxolitinib for over a year. Results Both patients experienced sustained, near-complete regrowth without hematologic or other complications after one year of treatment. Oral ruxolitinib effectively and safely treated alopecia in two women. Conclusions Ruxolitinib should be considered for cases of unresponsive alopecia in the community. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text